1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Herpes Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Herpes Treatment Market, by Therapeutic Type
8.1.1. Nucleoside & Nucleotide Antivirals
8.1.1.1. Market Revenue and Forecast
8.1.2. Acyclovir
8.1.2.1. Market Revenue and Forecast
8.1.3. Valacyclovir
8.1.3.1. Market Revenue and Forecast
8.1.4. Famciclovir
8.1.4.1. Market Revenue and Forecast
8.1.5. Non-nucleoside Antivirals
8.1.5.1. Market Revenue and Forecast
8.1.6. Topical / Localized Agents
8.1.6.1. Market Revenue and Forecast
8.1.7. Combination & Adjunct Therapies
8.1.7.1. Market Revenue and Forecast
8.1.8. Emerging Biologics & Novel Agents
8.1.8.1. Market Revenue and Forecast
9.1. Herpes Treatment Market, by Route of Administration
9.1.1. Oral Therapies
9.1.1.1. Market Revenue and Forecast
9.1.2. Topical Agents
9.1.2.1. Market Revenue and Forecast
9.1.3. Injectable Therapies
9.1.3.1. Market Revenue and Forecast
9.1.4. Others (e.g., intralesional)
9.1.4.1. Market Revenue and Forecast
10.1. Herpes Treatment Market, by Treatment Approach
10.1.1. Outbreak Suppression/Episodic Treatment
10.1.1.1. Market Revenue and Forecast
10.1.2. Chronic Suppression Therapy
10.1.2.1. Market Revenue and Forecast
10.1.3. Symptomatic Relief Therapies
10.1.3.1. Market Revenue and Forecast
10.1.4. Recurrent / Preventive Management
10.1.4.1. Market Revenue and Forecast
11.1. Herpes Treatment Market, by End User
11.1.1. Hospitals & Specialty Clinics
11.1.1.1. Market Revenue and Forecast
11.1.2. Dermatology & STD Clinics
11.1.2.1. Market Revenue and Forecast
11.1.3. Retail Pharmacies
11.1.3.1. Market Revenue and Forecast
11.1.4. Online Pharmacies & E-commerce
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapeutic Type
12.1.2. Market Revenue and Forecast, by Route of Administration
12.1.3. Market Revenue and Forecast, by Treatment Approach
12.1.4. Market Revenue and Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapeutic Type
12.1.5.2. Market Revenue and Forecast, by Route of Administration
12.1.5.3. Market Revenue and Forecast, by Treatment Approach
12.1.5.4. Market Revenue and Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapeutic Type
12.1.6.2. Market Revenue and Forecast, by Route of Administration
12.1.6.3. Market Revenue and Forecast, by Treatment Approach
12.1.6.4. Market Revenue and Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapeutic Type
12.2.2. Market Revenue and Forecast, by Route of Administration
12.2.3. Market Revenue and Forecast, by Treatment Approach
12.2.4. Market Revenue and Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapeutic Type
12.2.5.2. Market Revenue and Forecast, by Route of Administration
12.2.5.3. Market Revenue and Forecast, by Treatment Approach
12.2.5.4. Market Revenue and Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapeutic Type
12.2.6.2. Market Revenue and Forecast, by Route of Administration
12.2.6.3. Market Revenue and Forecast, by Treatment Approach
12.2.6.4. Market Revenue and Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapeutic Type
12.2.7.2. Market Revenue and Forecast, by Route of Administration
12.2.7.3. Market Revenue and Forecast, by Treatment Approach
12.2.7.4. Market Revenue and Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapeutic Type
12.2.8.2. Market Revenue and Forecast, by Route of Administration
12.2.8.3. Market Revenue and Forecast, by Treatment Approach
12.2.8.4. Market Revenue and Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapeutic Type
12.3.2. Market Revenue and Forecast, by Route of Administration
12.3.3. Market Revenue and Forecast, by Treatment Approach
12.3.4. Market Revenue and Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapeutic Type
12.3.5.2. Market Revenue and Forecast, by Route of Administration
12.3.5.3. Market Revenue and Forecast, by Treatment Approach
12.3.5.4. Market Revenue and Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapeutic Type
12.3.6.2. Market Revenue and Forecast, by Route of Administration
12.3.6.3. Market Revenue and Forecast, by Treatment Approach
12.3.6.4. Market Revenue and Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapeutic Type
12.3.7.2. Market Revenue and Forecast, by Route of Administration
12.3.7.3. Market Revenue and Forecast, by Treatment Approach
12.3.7.4. Market Revenue and Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapeutic Type
12.3.8.2. Market Revenue and Forecast, by Route of Administration
12.3.8.3. Market Revenue and Forecast, by Treatment Approach
12.3.8.4. Market Revenue and Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapeutic Type
12.4.2. Market Revenue and Forecast, by Route of Administration
12.4.3. Market Revenue and Forecast, by Treatment Approach
12.4.4. Market Revenue and Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapeutic Type
12.4.5.2. Market Revenue and Forecast, by Route of Administration
12.4.5.3. Market Revenue and Forecast, by Treatment Approach
12.4.5.4. Market Revenue and Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapeutic Type
12.4.6.2. Market Revenue and Forecast, by Route of Administration
12.4.6.3. Market Revenue and Forecast, by Treatment Approach
12.4.6.4. Market Revenue and Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapeutic Type
12.4.7.2. Market Revenue and Forecast, by Route of Administration
12.4.7.3. Market Revenue and Forecast, by Treatment Approach
12.4.7.4. Market Revenue and Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapeutic Type
12.4.8.2. Market Revenue and Forecast, by Route of Administration
12.4.8.3. Market Revenue and Forecast, by Treatment Approach
12.4.8.4. Market Revenue and Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapeutic Type
12.5.2. Market Revenue and Forecast, by Route of Administration
12.5.3. Market Revenue and Forecast, by Treatment Approach
12.5.4. Market Revenue and Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapeutic Type
12.5.5.2. Market Revenue and Forecast, by Route of Administration
12.5.5.3. Market Revenue and Forecast, by Treatment Approach
12.5.5.4. Market Revenue and Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapeutic Type
12.5.6.2. Market Revenue and Forecast, by Route of Administration
12.5.6.3. Market Revenue and Forecast, by Treatment Approach
12.5.6.4. Market Revenue and Forecast, by End User
13.1. GSK plc
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Emcure Pharmaceuticals Ltd.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Carlsbad Tech
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Glenmark Pharmaceuticals Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Viatris, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Fresenius Kabi AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Teva Pharmaceuticals Industries Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Apotex Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sanofi
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Sanofi
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
